TWI762534B - 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 - Google Patents

作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 Download PDF

Info

Publication number
TWI762534B
TWI762534B TW106143023A TW106143023A TWI762534B TW I762534 B TWI762534 B TW I762534B TW 106143023 A TW106143023 A TW 106143023A TW 106143023 A TW106143023 A TW 106143023A TW I762534 B TWI762534 B TW I762534B
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
heteroaryl
chloro
cycloalkyl
Prior art date
Application number
TW106143023A
Other languages
English (en)
Chinese (zh)
Other versions
TW201833113A (zh
Inventor
李菁
趙海波
志偉 王
Original Assignee
英屬開曼群島商百濟神州有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英屬開曼群島商百濟神州有限公司 filed Critical 英屬開曼群島商百濟神州有限公司
Publication of TW201833113A publication Critical patent/TW201833113A/zh
Application granted granted Critical
Publication of TWI762534B publication Critical patent/TWI762534B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW106143023A 2016-12-07 2017-12-07 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物 TWI762534B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
WOPCT/CN2016/108897 2016-12-07

Publications (2)

Publication Number Publication Date
TW201833113A TW201833113A (zh) 2018-09-16
TWI762534B true TWI762534B (zh) 2022-05-01

Family

ID=62491736

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106143023A TWI762534B (zh) 2016-12-07 2017-12-07 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物
TW111114434A TW202233190A (zh) 2016-12-07 2017-12-07 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111114434A TW202233190A (zh) 2016-12-07 2017-12-07 作為PI3Kδ抑制劑的咪唑並[1,5-A]吡衍生物

Country Status (16)

Country Link
US (2) US11136323B2 (cg-RX-API-DMAC10.html)
EP (1) EP3551630A4 (cg-RX-API-DMAC10.html)
JP (2) JP7064495B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190091339A (cg-RX-API-DMAC10.html)
CN (2) CN114805366A (cg-RX-API-DMAC10.html)
AU (2) AU2017372377B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019011847A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045959A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991355A1 (cg-RX-API-DMAC10.html)
IL (2) IL266986B (cg-RX-API-DMAC10.html)
MX (1) MX394882B (cg-RX-API-DMAC10.html)
NZ (1) NZ754944A (cg-RX-API-DMAC10.html)
SG (1) SG10201912192RA (cg-RX-API-DMAC10.html)
TW (2) TWI762534B (cg-RX-API-DMAC10.html)
WO (1) WO2018103688A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201903286B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394882B (es) 2016-12-07 2025-03-24 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
NZ761680A (en) * 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Pi3kデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
TW202327611A (zh) * 2021-09-14 2023-07-16 英屬開曼群島商百濟神州有限公司 使用btk抑制劑和p13激酶抑制劑的組合治療癌症之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
US8653089B2 (en) 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use
CA2860723A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
KR20160013204A (ko) * 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
MX394882B (es) 2016-12-07 2025-03-24 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
NZ761680A (en) 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
IL266986A (en) 2019-07-31
SG10201912192RA (en) 2020-02-27
ZA201903286B (en) 2021-01-27
JP7064495B2 (ja) 2022-05-10
TW202233190A (zh) 2022-09-01
AU2022203737A1 (en) 2022-06-23
NZ754944A (en) 2023-02-24
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
US20220098202A1 (en) 2022-03-31
EP3551630A4 (en) 2020-07-15
IL290419B (en) 2022-10-01
IL266986B (en) 2022-03-01
WO2018103688A1 (en) 2018-06-14
EP3551630A1 (en) 2019-10-16
JP2022090051A (ja) 2022-06-16
CA3045959A1 (en) 2018-06-14
CN110267959B (zh) 2022-05-27
KR20190091339A (ko) 2019-08-05
TW201833113A (zh) 2018-09-16
MX394882B (es) 2025-03-24
EA201991355A1 (ru) 2019-11-29
IL290419B2 (en) 2023-02-01
AU2017372377A1 (en) 2019-07-18
JP2020500909A (ja) 2020-01-16
US11136323B2 (en) 2021-10-05
CN114805366A (zh) 2022-07-29
AU2017372377B2 (en) 2022-03-03
CN110267959A (zh) 2019-09-20
IL290419A (en) 2022-04-01
BR112019011847A2 (pt) 2019-10-29
US20190367523A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
AU2022287562A1 (en) 2-amino-N-heteroaryl-nicotinamides as NAV1.8 inhibitors
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
US11725012B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
CN105566321B (zh) 杂芳化合物及其在药物中的应用
US20220289712A1 (en) Aminopyrazine compounds as hpk1 inhibitor and the use thereof
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
CA2921959A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
TWI817956B (zh) 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
CN121013849A (zh) 作为wrn抑制剂的杂环化合物
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
TW202214634A (zh) 雜環化合物及其衍生物
HK40091563B (en) Pyrimidinone compounds and uses thereof
HK40091563A (en) Pyrimidinone compounds and uses thereof
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees